| Total (tested) | CD20-negative DLBCL(n = 28) | CD20-positive DLBCL(n = 84) | P |
---|---|---|---|---|
IHC Subtypes | Â | Â | Â | Â |
GCB | 26(48.1%) | 5(22.7%) | 21(65.6%) | 0.002 |
non-GCB | 28(51.9%) | 17(77.3%) | 11(34.4%) | Â |
Ki-67 | Â | Â | Â | Â |
≥80% | 30(42.3%) | 17(70.8%) | 13(27.7%) | <0.001 |
<80% | 41(57.7%) | 7(29.2%) | 34(72.3%) | Â |
BCL-2 | Â | Â | Â | Â |
Positive | 37(54.4%) | 13(65%) | 24(50%) | 0.258 |
Negative | 31(45.6%) | 7(35%) | 24(50%) | Â |
EBERs | Â | Â | Â | Â |
Positive | 2(6.9%) | 1(4.8%) | 1(12.5%) | 0.483 |
Negative | 27(93.1%) | 20(95.2%) | 7(87.5%) | Â |
CD30 | Â | Â | Â | Â |
Positive | 14(19.4%) | 9(36%) | 5(10.6%) | 0.023 |
Negative | 58(80.6%) | 16(64%) | 42(89.4%) | Â |
ALK | Â | Â | Â | Â |
Positive | 7(20.6%) | 5(20.8%) | 2(20%) | 1 |
Negative | 27(79.4%) | 19(79.2%) | 8(80%) | Â |
Specified DLBCL | Â | Â | Â | Â |
ALK-positive LBCL | 5(4.5%) | 5(17.9%) | 0(0) | 0.001 |
PBL | 2(1.8%) | 2(7.1%) | 0(0) | 0.061 |
PEL | 0(0) | 0(0) | 0(0) | 1 |
DLBCL with PD | 4(3.6%) | 3(10.7%) | 1(1.2%) | 0.078 |